February 9, 2015 | The Israeli company developing drug delivery platforms, SteadyMed Therapeutics filed with the US Securities and Exchange Commission to raise $55 million in a NASDAQ IPO. The company made the move just ten days after raising $12.2 million in equity financing. The reported underwriters for the IPO are Wells Fargo, RBC and JP Morgan. SteadyMed was founded as part of the RAD Biomed incubator. The company is headquartered in San Ramon, California, but a good deal of product development still occurs in Rehovot, Israel. SteadyMed was founded in 2005 and has developed the PatchPump for drug delivery and other novel drug delivery methods.